Drug Profile


Alternative Names: DARA - Pharmacopeia; DARA - Retrophin; PS-433540; RE-021

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Retrophin
  • Class Antihypertensives; Isoxazoles; Small molecules; Spiro compounds; Sulfonamides
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Focal segmental glomerulosclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Focal segmental glomerulosclerosis
  • Discontinued Hypertension

Most Recent Events

  • 03 Nov 2017 Additional efficacy data from the phase II DUET trial in Focal segmental glomerulosclerosis released by Retrophin
  • 09 Aug 2017 Retrophin announces intention to submit phase III trial protocol to the US FDA for Focal segmental glomerulosclerosis
  • 01 Jun 2017 Retrophin has patent protection for the use of sparsentan for treating glomerulosclerosis in Europe and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top